

FIRST VENTURE TECHNOLOGIES CORP.

(TSX-V: FEB - \$0.95)

FURTHER ADVANCEMENT IN PRODUCT TRIALS**South American Product Trials**

First Venture Technologies Corp. ("First Venture" or the "Company") has released the final analysis of the results from its commercial product trials of its urea-degrading wine yeast in South America.

In July 2007, the Company reported that it had achieved ethyl carbamate reductions ranging as high as 76%-92% in wines made with its proprietary yeasts, compared with control yeasts.

First Venture is now reporting that there are no sensory (taste and smell) or fermentation performance differences between wines made with its urea-degrading yeast and the control yeasts. This is consistent with recent results from North American commercial trials.

North American Product Trials

The Company is conducting its second season of product trials in North America, and various technical projects are underway to refine the yeast product line and to secure production and inventory (from third party yeast producers initially). In addition, the Company is pursuing new markets for its brandy, sake and bread yeast strains that have proven efficacious in lab trials.

RATINGS HISTORY

The following table shows the extent of the eResearch research material on the Company:

Date	Type	Recommendation	Stock Price	Target Price
February 1, 2007	Initiating	Speculative Buy	\$0.80	\$1.25
March 27, 2007	Commentary	No Change	\$1.17	No Change
April 23, 2007	Bulletin	Under Review	\$1.50	Under Review
April 30, 2007	Update	Speculative Buy	\$1.40	Raised to \$2.50
July 12, 2007	Bulletin	No Change	\$1.56	No Change
August 13, 2007	Update	No Change	\$1.29	No Change
September 18, 2007	Bulletin	No Change	\$1.52	No Change

RECOMMENDATION

We continue to recommend First Venture Technologies Corp. as a Speculative Buy, with a 12 month Target Price of \$2.50 (unchanged). At the current depressed share price of \$0.95, eResearch believes First Venture Technologies Corp. offers excellent value.